Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07740733
PHASE3

Phase I/III Clinical Trial of Adsorbed Tetanus Vaccine

Sponsor: Beijing Minhai Biotechnology Co., Ltd

View on ClinicalTrials.gov

Summary

The study aimed to evaluate the safety and immunogenicity of an adsorbed tetanus vaccine in healthy individuals between 18 and 43 years of age.

Official title: A Randomized, Blinded, Parallel-Controlled Phase I/III Clinical Trial to Evaluate the Safety and Immunogenicity of Adsorbed Tetanus Vaccine in Healthy Individuals Aged 18-43 Years

Key Details

Gender

All

Age Range

18 Years - 43 Years

Study Type

INTERVENTIONAL

Enrollment

1240

Start Date

2024-02-29

Completion Date

2024-12-23

Last Updated

2026-08-03

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Tetanus Toxoid (Adsorbed)

The study group's vaccines had been produced by Beijing Minhai Biotechnology Co., Ltd. Liquid formulation. 0.5 mL/vial.

BIOLOGICAL

Tetanus Toxoid (Adsorbed)

The manufacture of control group vaccines were Chengdu Olymvax Biopharmaceuticals Inc. Liquid formulation. 0.5 mL/vial.

Locations (1)

Guangdong Provincial Center for Diseases Control and Prevention

Guangzhou, Guangdong, China